FDA approves Blenrep for relapsed or refractory multiple myeloma

Published Date: 31 Oct 2025

The U.S. Food and Drug Administration approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Ultrasonography of hepatocellular carcinoma: From diagnosis to prognosis

2.

US Counties Suffered Significantly from a Lack of Psychiatric Care.

3.

Research suggests peer support may lower depression, stress among cancer patients in low-resource settings

4.

Sydney researchers identify new tools to improve cancer diagnosis and treatment.

5.

Cancer Diagnoses Still Lagging; Cancer and Family Health; New Type of Lung Cancer


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot